Media stories about Quotient Limited (NASDAQ:QTNT) have been trending positive recently, according to Accern. Accern rates the sentiment of press coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Quotient Limited earned a coverage optimism score of 0.26 on Accern’s scale. Accern also assigned media stories about the company an impact score of 45.1726755459986 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Shares of Quotient Limited (NASDAQ:QTNT) traded up 0.96% on Friday, reaching $5.26. 33,415 shares of the company’s stock were exchanged. Quotient Limited has a 12 month low of $3.22 and a 12 month high of $8.20. The firm’s 50 day moving average price is $4.38 and its 200-day moving average price is $5.98. The company’s market capitalization is $75.62 million.
Quotient Limited (NASDAQ:QTNT) last released its quarterly earnings data on Monday, August 7th. The company reported ($0.55) EPS for the quarter, hitting analysts’ consensus estimates of ($0.55). Quotient Limited had a negative return on equity of 13,050.41% and a negative net margin of 381.66%. The firm had revenue of $6.83 million for the quarter, compared to the consensus estimate of $5.70 million. On average, equities analysts anticipate that Quotient Limited will post ($2.01) EPS for the current year.
A number of research analysts have weighed in on QTNT shares. BTIG Research reaffirmed a “buy” rating and set a $12.00 price target on shares of Quotient Limited in a research report on Thursday, August 31st. Zacks Investment Research raised shares of Quotient Limited from a “sell” rating to a “hold” rating in a research report on Wednesday, August 9th. Finally, ValuEngine raised shares of Quotient Limited from a “strong sell” rating to a “sell” rating in a research report on Friday, June 30th.
In other Quotient Limited news, insider D J. Paul E. Cowan sold 100,000 shares of the company’s stock in a transaction that occurred on Monday, September 18th. The stock was sold at an average price of $4.41, for a total transaction of $441,000.00. Following the completion of the sale, the insider now owns 26,666 shares of the company’s stock, valued at $117,597.06. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider D J. Paul E. Cowan sold 90,580 shares of the company’s stock in a transaction that occurred on Wednesday, July 19th. The stock was sold at an average price of $6.39, for a total value of $578,806.20. Following the sale, the insider now directly owns 26,666 shares of the company’s stock, valued at approximately $170,395.74. The disclosure for this sale can be found here. Insiders have sold 365,612 shares of company stock valued at $1,884,079 in the last ninety days. Company insiders own 29.00% of the company’s stock.
Quotient Limited Company Profile
Quotient Limited is a diagnostics company. The Company focuses on blood grouping and donor disease screening, which is referred to as transfusion diagnostics. It is engaged in developing, manufacturing and commercializing conventional reagent products used for blood grouping within the global transfusion diagnostics market.
What are top analysts saying about Quotient Limited? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Quotient Limited and related companies.